Journal article icon

Journal article

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Abstract:

Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.2217/fon-2020-1048

Authors


More by this author
Role:
Author
ORCID:
0000-0002-6912-8569
More by this author
Role:
Author
ORCID:
0000-0002-6794-7229
More by this author
Role:
Author
ORCID:
0000-0002-0062-6607
Expand authors...
Sierra Oncology Ltd. (Sponsor) More from this funder
Publisher:
Future Medicine Publisher's website
Journal:
Future Oncology Journal website
Volume:
17
Issue:
12
Pages:
1449-1458
Publication date:
2021-01-11
Acceptance date:
2020-12-14
DOI:
EISSN:
1744-8301
ISSN:
1479-6694
Pmid:
33423550
Language:
English
Keywords:
Pubs id:
1156862
Local pid:
pubs:1156862
Deposit date:
2021-01-21

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP